Clinical characteristics and drug treatment of the study population
| Healthy pregn | RA pregn | RA non-pregn | AS pregn | AS non-pregn | |
|---|---|---|---|---|---|
| Values are n, n (%), or mean (range). | |||||
| *Parity, number of children born. | |||||
| †Prednisone <10 mg per day. | |||||
| AS, ankylosing spondylitis; DMARD, disease modifying antirheumatic drug;n, number; non-pregn, non-pregnant; NSAID, non-steroidal anti-inflammatory drug; pregn, pregnant; RA, rheumatoid arthritis. | |||||
| n | 29 | 10 | 40 | 10 | 16 |
| Age (years) | 31 (20 to 39) | 29 (23 to 35) | 34 (20 to 40) | 31 (22 to 37) | 33 (19 to 41) |
| Disease duration (years) | – | 6 (0 to 24) | 6 (0 to 17) | 10 (2 to 14) | 8 (0 to 21) |
| Parity* | |||||
| 0 | 18 | 7 | 18 | 6 | 7 |
| 1 | 8 | 3 | 10 | 4 | 2 |
| 2 | 3 | 0 | 9 | 0 | 5 |
| 3 | 0 | 0 | 3 | 0 | 2 |
| On NSAID | |||||
| Non-pregnant, | – | – | 33 (83%) | – | 13 (81%) |
| During pregnancy | – | 2 (20%) | – | 4 (40%) | – |
| Postpartum | – | 4 (40%) | – | 7 (70%) | – |
| On prednisone† | |||||
| Non-pregnant | – | – | 22 (55%) | – | 4 (25%) |
| During pregnancy | – | 2 (20%) | – | 0 (0%) | – |
| Postpartum | – | 3 (30%) | – | 1 (1%) | – |
| On DMARD | |||||
| Non-pregnant | – | – | 35 (88%) | – | 7 (44%) |
| During pregnancy | – | 3 (30%) | – | 0 (0%) | – |
| Postpartum | – | 6 (60%) | – | 0 (0%) | – |